[18F]FDOPA PET and clinical features in parkinsonism due to manganism

Mov Disord. 2005 Apr;20(4):492-496. doi: 10.1002/mds.20381.

Abstract

Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[18F]fluorodopa ([18F]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [18F]FDOPA PET demonstrated relatively symmetric and severely reduced [18F]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [18F]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antiparkinson Agents / therapeutic use
  • Brain / metabolism*
  • Carbidopa / therapeutic use
  • Drug Combinations
  • Female
  • Fluorodeoxyglucose F18*
  • Gait
  • Humans
  • Levodopa / therapeutic use
  • Magnetic Resonance Imaging
  • Manganese Poisoning / blood*
  • Manganese Poisoning / complications*
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / etiology*
  • Parkinson Disease / pathology*
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*

Substances

  • Antiparkinson Agents
  • Drug Combinations
  • Radiopharmaceuticals
  • carbidopa, levodopa drug combination
  • Fluorodeoxyglucose F18
  • Levodopa
  • Carbidopa